Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower on Wednesday. On Tuesday, the company disclosed a private placement that aims to raise up to $23.6 million.

• Bluejay Diagnostics stock is trading at depressed levels. What’s next for BJDX stock?

Details

In particular, the company entered into a purchase and sale deal of 3,655,917 shares of common shares at a price of $2.325 per share.

The offering includes $8.5 million upfront, with potential additional gross proceeds of approximately $15.1 million upon the exercise of warrants.

The company intends to extend its cash runway into early 2027 as it prepares for FDA submission and commercialization of its products.

Partnership with Argonaut Manufacturing Services 

On Tuesday, the company shares soared as it announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of Bluejay's Symphony platform.

The partnership is designed to support Bluejay's broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives.

In addition, the partnership is intended to strengthen Bluejay's future commercial infrastructure by supporting broader product distribution across the U.S., enhancing supply chain resilience, and reducing potential risks associated with international sourcing and import tariffs.

Bluejay Diagnostics (BJDX) Business Overview and Product Pipeline

Bluejay Diagnostics is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression.

Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

The recent capital raise is crucial for Bluejay as it seeks to navigate the regulatory landscape and bring its innovative testing solutions to market. This funding will support the company’s efforts to enhance its product offerings and expand its market presence in the medical diagnostics field.

How Bluejay Diagnostics (BJDX) Ranks On Momentum and Other Factors

Below is the Benzinga Edge scorecard for Bluejay Diagnostics, highlighting its strengths and weaknesses compared to the broader market:

– Momentum: Strong (Score: 77.52) — Stock is outperforming the broader market.

The Verdict: Bluejay Diagnostics’s Benzinga Edge signal reveals a momentum-driven story, indicating that while the stock has strong momentum, the recent price action may suggest a need for caution as it approaches overbought conditions.

BJDX Stock Price Activity: Bluejay Diagnostics shares were trading down 1.84% at $4.26 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock